Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-07-15 Sale |
2022-07-19 4:40 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
46,034 | $30 | $1,381,020 | 103,855 (Direct) |
View |
| 2022-07-13 Sale |
2022-07-15 4:40 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
1,916 | $30 | $57,480 | 149,889 (Direct) |
View |
| 2022-05-11 Sale |
2022-05-13 4:37 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $41.9 | $222,050 | 151,805 (Direct) |
View |
| 2022-04-11 Sale |
2022-04-13 4:36 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $62.77 | $332,705 | 157,105 (Direct) |
View |
| 2022-04-06 Sale |
2022-04-08 4:21 pm |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
1,728 | $65 | $112,320 | 8,002 (Direct) |
View |
| 2022-04-04 Sale |
2022-04-06 4:49 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
7,950 | $60 | $477,000 | 162,405 (Direct) |
View |
| 2022-04-01 Sale |
2022-04-05 4:31 pm |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
864 | $57.49 | $49,675 | 9,730 (Direct) |
View |
| 2022-03-11 Sale |
2022-03-15 4:37 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $53.38 | $141,449 | 170,355 (Direct) |
View |
| 2022-02-11 Sale |
2022-02-15 4:26 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $52.06 | $137,965 | 173,005 (Direct) |
View |
| 2022-01-11 Sale |
2022-01-13 4:39 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $53.75 | $142,447 | 175,655 (Direct) |
View |
| 2022-01-05 Sale |
2022-01-07 4:35 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $60 | $159,000 | 178,305 (Direct) |
View |
| 2022-01-03 Sale |
2022-01-05 7:14 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
47,651 | $57.84 | $2,756,116 | 232,727 (Indirect) |
View |
| 2021-12-13 Sale |
2021-12-15 4:48 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $50.4 | $133,558 | 276,945 (Direct) |
View |
| 2021-12-01 Sale |
2021-12-03 5:05 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
47,651 | $54.09 | $2,577,376 | 251,536 (Indirect) |
View |
| 2021-11-10 Sale |
2021-11-12 4:40 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
21,200 | $59.91 | $1,270,058 | 286,810 (Direct) |
View |
| 2021-11-04 Sale |
2021-11-05 5:06 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
10,600 | $50 | $530,000 | 204,805 (Direct) |
View |
| 2021-11-01 Sale |
2021-11-03 7:04 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
47,651 | $42.12 | $2,007,129 | 270,346 (Indirect) |
View |
| 2021-10-19 Sale |
2021-10-21 4:29 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
8,598 | $38.2 | $328,441 | 289,156 (Indirect) |
View |
| 2021-10-14 Sale |
2021-10-18 8:35 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
26,367 | $38.56 | $1,016,653 | 292,550 (Indirect) |
View |
| 2021-10-01 Sale |
2021-10-05 8:47 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
12,686 | $40.1 | $508,755 | 302,958 (Indirect) |
View |
| 2021-09-27 Sale |
2021-09-29 4:39 pm |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
95,302 | $41.17 | $3,924,003 | 307,966 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-16 Option Award |
2023-02-17 4:13 pm |
N/A 2033-02-15 |
Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:42 pm |
N/A 2023-10-07 |
Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner |
7,176 | $0 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:42 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner |
7,176 | $0.0001 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:40 pm |
N/A 2023-10-07 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
7,176 | $0 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:40 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
7,176 | $0.0001 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:38 pm |
N/A 2023-10-07 |
Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner |
7,176 | $0 | 1,226,412 (Indirect) |
View |
| 2022-11-29 Exercise |
2022-11-30 4:38 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner |
7,176 | $0.0001 | 1,226,412 (Indirect) |
View |
| 2022-07-15 Exercise |
2022-07-19 4:40 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
46,034 | $0 | 103,855 (Direct) |
View |
| 2022-07-15 Exercise |
2022-07-19 4:40 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
46,034 | $0.3 | 103,855 (Direct) |
View |
| 2022-07-13 Exercise |
2022-07-15 4:40 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
1,916 | $0 | 149,889 (Direct) |
View |
| 2022-07-13 Exercise |
2022-07-15 4:40 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
1,916 | $0.3 | 149,889 (Direct) |
View |
| 2022-06-14 Exercise |
2022-06-14 6:57 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
9,400 | $0 | 151,805 (Direct) |
View |
| 2022-06-14 Exercise |
2022-06-14 6:57 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
9,400 | $0.3 | 151,805 (Direct) |
View |
| 2022-06-09 Exercise |
2022-06-10 4:12 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer |
5,000 | $0 | 257,678 (Direct) |
View |
| 2022-06-09 Exercise |
2022-06-10 4:12 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer |
5,000 | $0.3 | 257,678 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:30 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:28 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | Knowles Julius Director |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:27 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:26 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:25 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | GORDON CARL L Director |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-06-01 Option Award |
2022-06-03 4:24 pm |
N/A 2032-05-31 |
Keros Therapeutics Inc. | KROS | Farzan Nima Director |
8,293 | $0 | 8,293 (Direct) |
View |
| 2022-05-11 Exercise |
2022-05-13 4:37 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0 | 151,805 (Direct) |
View |
| 2022-05-11 Exercise |
2022-05-13 4:37 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0.3 | 151,805 (Direct) |
View |
| 2022-04-11 Exercise |
2022-04-13 4:36 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0 | 157,105 (Direct) |
View |
| 2022-04-11 Exercise |
2022-04-13 4:36 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0.3 | 157,105 (Direct) |
View |
| 2022-04-06 Exercise |
2022-04-08 4:21 pm |
N/A 2030-04-07 |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
1,728 | $0 | 8,002 (Direct) |
View |
| 2022-04-06 Exercise |
2022-04-08 4:21 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
1,728 | $16 | 8,002 (Direct) |
View |
| 2022-04-04 Exercise |
2022-04-06 4:49 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
7,950 | $0 | 162,405 (Direct) |
View |
| 2022-04-04 Exercise |
2022-04-06 4:49 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
7,950 | $0.3 | 162,405 (Direct) |
View |
| 2022-04-01 Exercise |
2022-04-05 4:31 pm |
N/A 2030-04-07 |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
864 | $0 | 9,730 (Direct) |
View |
| 2022-04-01 Exercise |
2022-04-05 4:31 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
864 | $16 | 9,730 (Direct) |
View |
| 2022-03-11 Exercise |
2022-03-15 4:37 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0 | 170,355 (Direct) |
View |
| 2022-03-11 Exercise |
2022-03-15 4:37 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0.3 | 170,355 (Direct) |
View |
| 2022-02-11 Exercise |
2022-02-15 4:26 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0 | 173,005 (Direct) |
View |
| 2022-02-11 Exercise |
2022-02-15 4:26 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0.3 | 173,005 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-03 4:45 pm |
N/A 2032-01-31 |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
100,000 | $0 | 100,000 (Direct) |
View |
Ownership |
2022-02-03 4:37 pm |
N/A 2029-09-18 |
Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer |
0 | $0 | 32,898 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 4:17 pm |
N/A 2032-01-20 |
Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer |
165,000 | $0 | 165,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 4:15 pm |
N/A 2032-01-20 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 4:14 pm |
N/A 2032-01-20 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 4:12 pm |
N/A 2032-01-20 |
Keros Therapeutics Inc. | KROS | Cooper Simon Peter Chief Medical Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2022-01-11 Exercise |
2022-01-13 4:39 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0 | 175,655 (Direct) |
View |
| 2022-01-11 Exercise |
2022-01-13 4:39 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0.3 | 175,655 (Direct) |
View |
| 2022-01-05 Exercise |
2022-01-07 4:35 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0 | 178,305 (Direct) |
View |
| 2022-01-05 Exercise |
2022-01-07 4:35 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0.3 | 178,305 (Direct) |
View |
| 2021-12-13 Exercise |
2021-12-15 4:48 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0 | 276,945 (Direct) |
View |
| 2021-12-13 Exercise |
2021-12-15 4:48 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
2,650 | $0.3 | 276,945 (Direct) |
View |
| 2021-11-10 Exercise |
2021-11-12 4:40 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
21,200 | $0 | 286,810 (Direct) |
View |
| 2021-11-10 Exercise |
2021-11-12 4:40 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
21,200 | $0.3 | 286,810 (Direct) |
View |
| 2021-11-04 Exercise |
2021-11-05 5:06 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
10,600 | $0 | 204,805 (Direct) |
View |
| 2021-11-04 Exercise |
2021-11-05 5:06 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
10,600 | $0.3 | 204,805 (Direct) |
View |
| 2021-08-17 Exercise |
2021-08-18 5:21 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
1,293 | $0 | 85,700 (Direct) |
View |
| 2021-08-17 Exercise |
2021-08-18 5:21 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
1,293 | $0.3 | 85,700 (Direct) |
View |